TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

TRACON Pharmaceuticals reports positive interim data, focuses on growth strategies

TRACON Pharmaceuticals showcased promising interim data from the ENVASARC trial, reflecting positive efficacy of ENVA treatment and strategic advancements in product development.
While facing challenges such as financial losses and regulatory compliance, TRACON's focus on cost-saving measures and operational efficiency positions it for sustainable growth.
The company's strong cash position, commitment to advancing its pipeline, and opportunities for collaboration and portfolio expansion signal a promising outlook for future growth and innovation.
By leveraging its product development platform and upcoming trial data releases, TRACON aims to drive value creation, financial stability, and regulatory compliance in the competitive pharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development, shares in the cost and risk of clinical development, and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States.

Expects to Report Results of Independent Data Monitoring Committee (IDMC) Mandated Interim Safety Reviews and Interim Efficacy Review in the Second Half of 2022 Expects to Report Results of Independent Data Monitoring Committee (IDMC) Mandated Interim Safety Reviews and Interim Efficacy Review in the Second Half of 2022

TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K.

AstraZeneca

Biogen

Entera Bio Ltd

Greenwich Lifesciences

GameStop

Longeveron

Roche Holding AG

Riot Blockchain

SPDR S&P Biotech ETF

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech Stocks appeared first on InvestorPlace.

Recession Fears are Creating a Golden Opportunity for Biotech Stocks

SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat hosted by Jason McCarthy, at the Maxim Group 2022 Virtual Growth Conference on Wednesday, March 30, 2022 at 1:30pm Eastern Time.

TRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth Conference

TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q4 2021 Results - Earnings Call Transcript

TRACON Pharmaceuticals (NASDAQ:TCON) Inc said it has ended its fiscal year 2021 with cash and equivalents of $24.1 million as of December 31, 2021, as the company outlined some key milestones for the coming year. TRACON noted that it anticipates an interim ENVASARC safety and efficacy data review by the Independent Data Monitoring Committee (IDMC) in the second half of 2022.

TRACON Pharmaceuticals ends FY2021 with $24.1M in the bank; reveals key milestones for 2022

Announced FDA Approval of Amended ENVASARC Protocol, ENVASARC Interim Efficacy Data on Track for 2H22 Initiating combination trial of proprietary CTLA-4 with envafolimab in 2022

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022 at 4:00pm Eastern Time.

TRACON Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

Patient dosing underway, interim efficacy data on track for second half 2022 Patient dosing underway, interim efficacy data on track for second half 2022

TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol

SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States, announced today that it will report its fourth quarter and full year 2021 financial and operating results after the close of U.S. financial markets on Tuesday, March 15, 2022. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

TRACON to Report Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 15, 2022

Baird said that it has initiated coverage of TRACON Pharmaceuticals (NASDAQ:TCON) Inc with an outperform rating and a $10 price target.  “We see a high 70% probability of success for envafolimab, which is currently in a pivotal trial, and could be the first subcutaneously delivered PD-1 inhibitor approved in the US,” the analysts said.

Baird initiates coverage of TRACON Pharmaceuticals with a price target of $10

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics today announced that the National Cancer Institute (NCI) has initiated a randomized Phase 2 trial of TRC102 in combination with chemoradiation in patients with stage III non-squamous non-small cell lung cancer (NCT05198830: https://clinicaltrials.gov/ct2/show/NCT05198830?term=TRC102&draw=2&rank=3).

TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute

AvePoint

Compass

Vacasa

ViewRay

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Scorching-Hot Stocks Trading Under $10 With Big-Time Upside Potential

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BIOCONNECT Virtual Conference, being held January 10-13, 2022.

TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

TRACON Pharmaceuticals (NASDAQ:TCON) Inc shared positive results from the Independent Data Monitoring Committee (IDMC) review of interim safety and efficacy data from its ongoing ENVASARC pivotal trial for envafolimab in soft tissue sarcoma, a rare type of cancer that begins in the tissues.  The San Diego company, which utilizes a capital-efficient product development platform to develop its clinical-stage pipeline of cancer therapies, said that for the ongoing ENVASARC pivotal trial, the IDMC recommended “continued accrual as planned in both cohort A of single agent envafolimab, and cohort B of envafolimab given with Yervoy (ipilimumab).

TRACON shares positive results from Independent Data Monitoring Committee review of ENVASARC pivotal trial interim data

Pre-specified Interim Analysis Concluded with Recommendation to Continue the ENVASARC Trial

TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial

TRACON Pharmaceuticals (NASDAQ:TCON) Inc reported that its partners had announced that envafolimab (KN035) had received marketing authorization from the Chinese National Medical Products Administration (NMPA) - the first approval of a subcutaneously administered checkpoint inhibitor. Envafolimab has been given the go-ahead for adults with microsatellite instability-high (MSI-H), or deficient MisMatch Repair (dMMR) advanced solid tumors.

TRACON Pharmaceuticals notes partners regulatory approval of Envafolimab in China

TRACON Pharmaceuticals wins regulatory approval of Envafolimab in China

First Approval of a Subcutaneously Administered Checkpoint Inhibitor

TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China

Bally's

Alphatec Hlds

ElectroCore Inc

Insider sales are generally a sign the market is about to drop, but not everyone's selling. Here are five companies with insider buying.

5 Stocks Insiders Are Still Buying (Even As Others Cash Out)

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies London Virtual Healthcare Conference, being held November 18-19, 2021.

TRACON Pharmaceuticals to Present at the Jefferies London Virtual Healthcare Conference

TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q3 2021 Results - Earnings Call Transcript

TRACON Pharmaceuticals (NASDAQ:TCON) Inc said it has ended its third quarter 2021 with cash and equivalents of $29.9 million as of September 30, 2021, as the company expects to file an investigational new drug application (IND) and initiate a Phase 1/2 trial of YH001 combined with envafolimab in soft tissue sarcoma subtypes in early 2022.    TRACON also noted it anticipates initiating trials of YH001 in other indications in combination with approved standard of care agents in late 2022.

TRACON Pharmaceuticals ends 3Q with $29.9M in the bank; plans to initiate Phase 1/2 trial of YH001 in early 2022

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced financial results for the third quarter ended September 30, 2021. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.

TRACON Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its third quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, November 3, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

TRACON to Report Third Quarter 2021 Financial Results and Company Highlights on November 3, 2021

TRACON Pharmaceuticals has bolstered its board with the appointment of Carol Lam, who was previously senior vice-president and deputy general counsel at chip giant Qualcomm, as a new director. Lam was at Qualcomm for over a decade, dealing with complex tax, antitrust and IP issues in China, as well as matters involving privacy, employment, and antitrust laws in Europe, said biopharma group TRACON.

News for TRACON Pharmaceuticals Stock (TCON)